Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Neurocentrx Pharma Ltd. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct art units and 2 distinct examiners. WHITE, DAWANNA SHAR-DAY is the busiest examiner for the company, overseeing 1 pending office action. The company's current prosecution involves 2 pending office actions, each handled by a different examiner.
The 2 distinct art units indicate that the company's current prosecution is spread across different technical specialties within the pharmaceutical field. WHITE, DAWANNA SHAR-DAY handles 1 pending office action, which represents one of the 2 pending matters in the portfolio. This 2 to 2 ratio of actions to examiners suggests a lack of examiner overlap for the current workload. Practitioners should note that the 2 distinct art units represent the primary regulatory environments for these matters.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WHITE, DAWANNA SHAR-DAY | 1 | 62.4% | +24.3% |
| COPPINS, JANET L | 1 | 72.6% | +26.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17253828 | NOVEL FORMULATIONS COMPRISING KETAMINE | COPPINS, JANET L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18257384 | ORAL COMPOSITIONS COMPRISING KETAMINE COMBINED WITH SUBCUTANEAL OR INTRAVENOUS KETAMINE FOR USE IN THE TREATMENT, CONTROL OR PREVENTION OF DEPRESSIVE DISORDERS | WHITE, DAWANNA SHAR-DAY | 73d overdue |
| 17253828 | NOVEL FORMULATIONS COMPRISING KETAMINE | COPPINS, JANET L | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18257384 | ORAL COMPOSITIONS COMPRISING KETAMINE COMBINED WITH SUBCUTANEAL OR INTRAVENOUS KETAMINE FOR USE IN THE TREATMENT, CONTROL OR PREVENTION OF DEPRESSIVE DISORDERS | WHITE, DAWANNA SHAR-DAY | 1627 | §103 | Final Rejection | 73d overdue | Pending | Jun 14, 2023 |
| 17253828 | NOVEL FORMULATIONS COMPRISING KETAMINE | COPPINS, JANET L | 1628 | §103§112 | Non-Final OA | — | Pending | Dec 18, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNeurocentrx Pharma Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Dawanna Shar-Day White has the most, with 1 of Neurocentrx Pharma Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
